subscribeSubscribe
ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program

ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program
BUSINESSWIRE
18 Apr 2023
Share Share
NPPA revises ceiling prices of 128 formulations

NPPA revises ceiling prices of 128 formulations
ECONOMIC TIMES
17 Jan 2023
Share Share
Merck Enters Collaboration with Nerviano to Develop PARP1 Selective Inhibitor

Merck Enters Collaboration with Nerviano to Develop PARP1 Selective Inhibitor
BUSINESSWIRE
22 Sep 2022
Share Share
OncXerna`s Upcoming ASCO Poster Featuring Data of PII Glioblastoma Trial

OncXerna`s Upcoming ASCO Poster Featuring Data of PII Glioblastoma Trial
GLOBENEWSWIRE
03 Jun 2022
Share Share
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival
BUSINESSWIRE
24 Mar 2022
Share Share
EpicentRx begins Phase I trial of paediatric CNS tumour treatment

EpicentRx begins Phase I trial of paediatric CNS tumour treatment
CLINICALTRIALSARENA
25 Feb 2022
Share Share
Novocure announces National reimbursement in Switzerland for Optune

Novocure announces National reimbursement in Switzerland for Optune
PHARMABIZ
15 Dec 2020
Share Share
Novocure Announces National Reimbursement in Switzerland for Optune®

Novocure Announces National Reimbursement in Switzerland for Optune®
BUSINESSWIRE
14 Dec 2020
Share Share
Novocure Announces National Reimbursement in Switzerland for Optune®

Novocure Announces National Reimbursement in Switzerland for Optune®
BUSINESSWIRE
14 Dec 2020
Share Share
Pelareorep-based combination therapy improves glioblastoma patient survival

Pelareorep-based combination therapy improves glioblastoma patient survival
Hannah Balfour EUROPEANPHARMACEUTICALREVIEW
24 Nov 2020
Share Share